          |
 |
2017 Agenda and Abstracts | < Previous Next >
2017 OMIG Abstract 18 Effect of NanoViricide Anti-viral Agents in Mouse Model of Acute Retinal Necrosis Purpose: To evaluate efficacy of nanoviricide anti-herpesvirus agents in mouse model of acute retinal necrosis (ARN). Methods: The right eyes of female Balb/c Mice, 6-12 weeks old, were injected intravitreally with 1x104 pfu of HSV-2 strain G. For all groups except acyclovir treatment, 2 μl of virus were mixed with 2 μl of vehicle or nanoviricide anti-viral agents, 20 μg, and then injected intravitreally once. One group was injected intravitreally with foscarnet, 20 mg/ml, that was pre-incubated with the virus. The infected, acyclovir-treated group received acyclovir by intraperitoneal injection (50 mg/Kg) 2 times per day for 7 days. Mice were euthanized at days 5, 7, 9, and 11 and infected right eyes were processed for outcome parameters; a) histopathological evaluation and b) viral titer analysis. For histopathology, the severity of retinal disease was quantified on H&E stained slides as described previously (Arch. Virol. 1997, 142:883). Viral titers were determined using a standard plaque assay on Vero cells. Results: Mice treated with the nanoviricide anti-herpesvirus compounds had significant reductions in HSV-2-induced histopathology and HSV-2 virus replication at all days evaluated as compared to treatment with vehicle. In contrast, mice treated with acyclovir or foscarnet did not show any significant reductions in in histopathology and viral replication. Conclusions: The nanoviricide anti-HSV-2 compounds were highly effective in prevention of viral-induced histopathology and virus replication. Disclosure: Boniuk (C), Brandt (S), Larsen (S), Kolb (S), Diwan (OP),Barton (E),Friedrich (E).
2017 Agenda and Abstracts | < Previous Next >
|
|
